Status:

NOT_YET_RECRUITING

Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis

Lead Sponsor:

University of Manchester

Conditions:

Respiration Disorders

Respiratory Failure

Eligibility:

All Genders

18+ years

Brief Summary

Aim of the research: To find out why antibiotics work differently in certain patients with severe pneumonia and sepsis. Background: Individuals can become very unwell from pneumonia, sometimes requir...

Eligibility Criteria

Inclusion

  • age ≥ 18 years;
  • admitted to intensive care and receiving at least one-organ supportive care;
  • treated for presumed or confirmed lower respiratory infection;
  • receiving or about to receive piperacillin/tazobactam as part of standard clinical care;
  • valid informed consent or enrolment through deferred consent pathway appropriate.

Exclusion

  • unlikely to survive 24 hours as judged by the treating physician;
  • study antimicrobial started more than 24 hours prior.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 30 2027

Estimated Enrollment :

119 Patients enrolled

Trial Details

Trial ID

NCT06977165

Start Date

September 1 2025

End Date

September 30 2027

Last Update

May 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Manchester

Manchester, Lancashire, United Kingdom, M13 9PL